Australian Clinical Labs (ASX:ACL) Debt-to-EBITDA : 1.80 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Australian Clinical Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$110.7 Mil. Australian Clinical Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was A$204.6 Mil. Australian Clinical Labs's annualized EBITDA for the quarter that ended in Dec. 2024 was A$175.3 Mil. Australian Clinical Labs's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 1.80.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Australian Clinical Labs's Debt-to-EBITDA or its related term are showing as below:

ASX:ACL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.72 Med: 1.7 Max: 1.82
Current: 1.72

During the past 5 years, the highest Debt-to-EBITDA Ratio of Australian Clinical Labs was 1.82. The lowest was 0.72. And the median was 1.70.

ASX:ACL's Debt-to-EBITDA is ranked worse than
53.7% of 108 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.635 vs ASX:ACL: 1.72

Australian Clinical Labs Debt-to-EBITDA Historical Data

The historical data trend for Australian Clinical Labs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs Debt-to-EBITDA Chart

Australian Clinical Labs Annual Data

Trend

Dec20

Jun21

Jun22

Jun23

Jun24

Debt-to-EBITDA

N/A

1.59

0.72

1.81

1.82

Australian Clinical Labs Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-EBITDA	Get a 7-Day Free Trial				1.71	1.98	2.21	1.61	1.80

Competitive Comparison of Australian Clinical Labs's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Australian Clinical Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australian Clinical Labs's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Australian Clinical Labs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Australian Clinical Labs's Debt-to-EBITDA for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(104.709	+	204.19)	/	169.65
	=	1.82

Australian Clinical Labs's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(110.697	+	204.622)	/	175.334
	=	1.80

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2024) EBITDA data.

Australian Clinical Labs (ASX:ACL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Australian Clinical Labs Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Australian Clinical Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168

Website

https://www.clinicallabs.com.au

Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.

Australian Clinical Labs Headlines

No Headlines